Mostrando 10 resultados de: 19
Filtros aplicados
Subtipo de publicación
Article(19)
Publisher
The Lancet(5)
Canadian Journal of Cardiology(2)
American Heart Journal(1)
BMJ Global Health(1)
Contemporary Clinical Trials(1)
Área temáticas
Enfermedades(11)
Farmacología y terapéutica(7)
Problemas sociales y servicios a grupos(4)
Salud y seguridad personal(3)
Cirugía y especialidades médicas afines(2)
Association of Sitting Time with Mortality and Cardiovascular Events in High-Income, Middle-Income, and Low-Income Countries
ArticleAbstract: Importance: High amounts of sitting time are associated with increased risks of cardiovascular diseaPalabras claves:Autores:Abat M.E.M., Alhabib K.F., Avezum A.J., Bangdiwala S.I., Basiak-Rasała A., Chifamba J., Dans A.M., DIaz R., Gupta R., Hu B., Iqbal R., Kelishadi R., Khatib R., Lakshmi P.V.M., Lanas F., Leach L., Lear S.A., Li S., Li W., Mazapuspavina M.Y., Mony P.K., Oguz A., PATRICIO LOPEZ -JARAMILLO, Rahman O., Rangarajan S., Rosengren A., Wielgosz A., Yeates K.E., Yin L., Yusuf S., Yusufali A.M.Fuentes:googlescopusAssociations of cereal grains intake with cardiovascular disease and mortality across 21 countries in prospective urban and rural epidemiology study: Prospective cohort study
ArticleAbstract: Objective To evaluate the association between intakes of refined grains, whole grains, and white ricPalabras claves:Autores:Alhabib K.F., Avezum A.J., Bo H., Chifamba J., Dans A.M., Dehghan M., DIaz R., Iqbal R., Jenkins D.J.A., Kelishadi R., Keskinler M.V., Khatib R., Lanas F.T., Lear S.A., Mohan V., Mony P.K., Noorhassim I., PATRICIO LOPEZ -JARAMILLO, Puoane T., Raj J.M., Rangarajan S., Rosengren A., Soman B., Swaminathan S., Teo K.K., Thomas T., Wei L., Xiaoyun L., Yeates K.E., Yusuf R., Yusuf S., Yusufali A.M., Zatońska K.Fuentes:googlescopusAvailability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study
ArticleAbstract: Background: Data are scarce on the availability and affordability of essential medicines for diabetePalabras claves:Autores:Alhabib K.F., Avezum A.J., Cheng X., Chifamba J., Chow C.K., Corsi D.J., Dagenais G.R., Dans A.M., Egbujie B.A., Gerstein H.C., Gupta R., Hu W., Iqbal R., Islam S., Keskinler M.V., Khatib R., Kruger L., Kumar R., Lanas F.T., Lear S.A., Mckee M., Mohammadifard N., Mohan V., Mony P.K., Noorhassim I., Orlandini A., PATRICIO LOPEZ -JARAMILLO, Ramasundarahettige C., Rangarajan S., Rosengren A., Teo K.K., Vijayakumar K., Wei L., Yeates K.E., Yusoff K., Yusuf R., Yusuf S., Yusufali A.M., Zatońska K., Zhou Y.Fuentes:googlescopusAvailability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries
ArticleAbstract: Objectives We aimed to examine the relationship between access to medicine for cardiovascular diseasPalabras claves:epidemiology, Health policy, prevention strategies, PUBLIC HEALTH, TreatmentAutores:Alhabib K.F., Avezum A.J., Bahonar A., Chifamba J., Chow C.K., Dans A.M., DIaz R., Gulec S., Gupta R., Hu B., Kazmi K., Khatib R., Kruger L., Kumar R., Lanas F.T., Lear S.A., Li W., Marschner S., Mckee M., Mony P.K., Nguyen T.N., PATRICIO LOPEZ -JARAMILLO, Rahman O., Rangarajan S., Rosengren A., Teo K.K., Yeates K.E., Yusoff K., Yusuf S., Yusufali A.M., Zatońska K.Fuentes:googlescopusFixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
ArticleAbstract: Background: In randomised controlled trials, fixed-dose combination treatments (or polypills) have bPalabras claves:Autores:Avezum A.J., Bangdiwala S.I., Bosch J.J., Castellano J.M., Dagenais G.R., Dans A.M., DIaz R., Fuster V., Gamra H., Gao P., Huffman M.D., Joseph P.G., Liu L., Lonn E.M., Malekzadeh R., Pais P., PATRICIO LOPEZ -JARAMILLO, Prabhakaran D., Rodgers A., Roshandel G., Sliwa K., Teo K.K., Xavier D., Yusuf S., Zhu J.Fuentes:googlescopusEffects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial
ArticleAbstract: Importance: Vascular risk factors are associated with cognitive decline but studies addressing indivPalabras claves:Autores:Bosch J.J., Dans A.M., Gao P., Joseph P.G., O'donnell M.J., Pais P., PATRICIO LOPEZ -JARAMILLO, Xavier D., Yusuf S.Fuentes:scopusNovel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
ArticleAbstract: Background: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drPalabras claves:Autores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Fodor G.J., Held C., Jansky P., Keltai K., Keltai M., Kim J.H., Kunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusModifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
ArticleAbstract: Background: Global estimates of the effect of common modifiable risk factors on cardiovascular diseaPalabras claves:Autores:Alhabib K.F., Avezum A.J., Bo H., Brauer M., Chifamba J., Dagenais G.R., Dans A.M., DIaz R., Gupta R., Hystad P., Iqbal R., Islam S., Joseph P.G., Kaur M., Kelishadi R., Khatib R., Kruger L., Kutty V.R., Lanas F.T., Lear S.A., Leong D.P., Mckee M., Mente A., Mohan V., Mony P.K., Oguz A., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Rahman O., Rangarajan S., Rosengren A., Teo K.K., Wei L., Wielgosz A., Yeates K.E., Yusoff K., Yusuf S., Yusufali A.M., Zatońska K.Fuentes:googlescopusSafety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
ArticleAbstract: Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. TPalabras claves:bacteria, CVD, Reflux, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopus